LCMC3: Clinical utility of SUVmax on preoperative 18F-FDG PET-CT in resectable NSCLC treated with neoadjuvant atezolizumab Meeting Abstract
| Authors: | Merritt, R.; Patterson, G. A.; Toloza, E. M.; Lee, J. M.; Raz, D. J.; Baciewicz, F.; Weyant, M.; Molena, D.; Isbell, J.; Kim, J.; Pass, H. I.; Bunn, P. A.; Johnson, B. E.; Kris, M. G.; Kwiatkowski, D. J.; Wistuba, I. I.; Bara, I.; Gasior, G.; Schulze, K.; Brandão, E.; Kneuertz, P. J.; Detterbeck, F.; Kozower, B.; Fontaine, J. P.; Park, B.; McNamee, C. J.; Blasberg, J. D.; Finley, D. J.; Nicholas, A.; Johnson, A.; Carbone, D. P.; Rusch, V. W. |
| Abstract Title: | LCMC3: Clinical utility of SUVmax on preoperative 18F-FDG PET-CT in resectable NSCLC treated with neoadjuvant atezolizumab |
| Meeting Title: | 2024 World Conference on Lung Cancer |
| Keywords: | neoadjuvant; suvmax; atezolizumab |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 19 |
| Issue: | 10 Suppl. |
| Meeting Dates: | 2024 Sep 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-10-01 |
| Start Page: | S240 |
| End Page: | S241 |
| Language: | English |
| ACCESSION: | WOS:001337925601204 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2024.09.431 |
| Notes: | Meeting Abstract: P2.07C.01 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
